Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan’s FY2014 Healthcare Spending Renews Record at 40.8 Trillion Yen
September 30, 2016
- MID-NET Working Group Kicks Off Discussions on Access Fees
September 30, 2016
- MHLW OKs Keytruda, Triple Hypertension Combo Micatrio and Other Drugs
September 29, 2016
- Novartis’ BRAF and MEK Inhibitors Get Orphan Status for NSCLC
September 29, 2016
- Sales of Sovaldi, Harvoni Peaked Out: MHLW
September 29, 2016
- Drug Costs Biggest Driver of Healthcare Spending Surge: Chuikyo JMA Rep
September 29, 2016
- Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
- Japan Inks Memorandums of Cooperation on Pharmacopoeias with US, Europe, China
September 27, 2016
- Lawmaker Group Calls for Launch of Int’l Center for Regenerative Medicine
September 27, 2016
- MHLW to Launch 2nd Round of Sakigake Invitations in Early October
September 26, 2016
- Opdivo under PMDA Review for Myocarditis and Other Risks
September 26, 2016
- Council Conditionally Approves 1st Technology for Use Under Patient-Initiated Mixed Care at Univ. of Tokyo Hospital
September 26, 2016
- Pharma, Govt Hold 1st Kanmin Taiwa Working Group Talks; Industry Calls for Trial-Friendly Environment, Discussions on Pricing
September 23, 2016
- Panel Backs Approval of Add’l Indication for J-TEC’s Cell Sheet JACE
September 21, 2016
- Combo Use of 2 Different Hep B Vaccines Produced Necessary Antibody Titer, No Serious ADRs: Report
September 21, 2016
- AMED Official Outlines Pre-Orphan Designation Support Scheme
September 20, 2016
- 3 Major Regulators Will Cooperate on Common Guidelines for Development of Antibacterial Drugs: PMDA Official
September 20, 2016
- As Personal Info Law Amendment Looms, Govt Official Tells Drug Makers to Review Info in Hand
September 16, 2016
- International Meeting of World Pharmacopoeias OKs GPhP Draft
September 16, 2016
- In-Kind Research Support Would Be Effective in Commercializing Drug Seeds: Paper
September 15, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…